Why Geovax Labs Shares Are Soaring Today

Geovax Labs Inc GOVX is trading significantly higher Friday after the company announced it presented data from ongoing studies of its preventive vaccine against COVID-19 at the European Society of Medicine General Assembly.

Using its novel Modified Virus Ankara-Virus Like Particle (GV-MVA-VLP) platform, GeoVax has developed a design strategy for vaccines expected to induce broader immunity through inclusion of multiple structural and nonstructural proteins from the target pathogen.

The GV-MVA-VLP platform is known to elicit a balanced humoral and cellular response against a range of immunogens, which could possibly make immune escape against emerging variants less likely. 

"In our studies, we observed the induction of functional antibodies and T-cell responses that mediate protection from infection and pathogenesis," said Mark Newman, chief scientific officer of Geovax Labs.

Geovax Labs is a U.S.-based clinical-stage biotechnology company engaged in developing immunotherapies and vaccines against cancers and infectious diseases.

Price Action: Geovax Labs has traded as high as $8.71 and as low as 25 cents over a 52-week period.

At last check Friday, the stock was up 58.40% at $6.80.